Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Erlotinib in Resected Early Stage EGFR-Mutated NSCLC
NCT00567359Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2007
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Dec 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00567359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567359.